National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Send to Printer

Understanding Cancer Series: Estrogen Receptors/SERMs
< Back to Main
    Posted: 01/28/2005    Updated: 04/27/2006    Reviewed: 09/01/2006
Slide 20  :  The Need for Better SERMs

The fact that tamoxifen blocks the action of estrogen in breast tissue while mimicking the action of estrogen in the uterus means that it functions as a SERM, selectively blocking or stimulating the estrogen receptors of different target tissues.

In addition to acting like estrogen in the uterus, tamoxifen resembles estrogen in its ability to lower LDL cholesterol levels. And in postmenopausal women, tamoxifen also resembles estrogen in its ability to preserve or increase bone density. Thus, aside from its tendency to increase the risk of uterine cancer, tamoxifen has a number of potentially beneficial properties.

As a result, scientists have been actively working on the development of other SERMs that might exhibit some of the beneficial properties of tamoxifen without sharing its potentially harmful effects.

The Need for Better SERMs